Table 2.

Clinical outcome of S-1 treatment for refractory thymic carcinoma

Clinical outcome	N° of patients (n = 14)
Response to chemotherapy	N (%)	95 % CI
Complete response	0 (0 %)
Partial response	6 (42.9 %)	[21.4–67.4]
Stable disease	6 (42.9 %)	[21.4–67.4]
Progression disease	2 (14.3 %)	[0.04–39.9]
Median response duration, moths [95 % CI]	8.1	[2.6–12.2]
Median overall survival, months [95 % CI]	30.0	[6.2–41.9]
1-year survival rate, %	68.8

CI confidence interval